Lilly, Boehringer collaborate on diabetes drugs

Jan 11, 2011

(AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.

Lilly, based in Indianapolis, loses this year for its top-selling drug, the anti-psychotic Zyprexa, and faces the loss of some other key patents in the next few years. The drugmaker said Tuesday that the deal with Boehringer Ingelheim offers the potential of boosting near-term revenue.

Lilly could receive more than $1 billion in future payments depending on how well the collaboration performs and whether the drugs under development reach certain sales milestones. Boehringer Ingelheim will be eligible for future payments totaling about $807 million.

The collaboration includes two Lilly insulins expected to enter late-stage testing this year and a treatment from Boehringer Ingelheim that is being reviewed by regulators.

Shares of Eli Lilly and Co. rose slightly in premarket trading.

Explore further: New treatment approved for rare form of hemophilia

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Eli Lilly halts development of Alzheimer's drug

Aug 17, 2010

(AP) -- Eli Lilly and Co. has stopped developing a potential Alzheimer's disease treatment at a time when the drugmaker is searching wide and far for new drugs to fill a large revenue hole that will form starting next year.

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

German firm shelves libido-boosting drug for women

Oct 09, 2010

German drug firm Boehringer Ingelheim has shelved development of a libido-booster for women after it was given the thumbs down by the US Food and Drug Administration (FDA), the company said.

FDA clears Eli Lilly's blood thinner Effient

Jul 10, 2009

(AP) -- The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

DanielHaszard
not rated yet Jan 11, 2011
Zyprexa damage Claims Still Unresolved-

Eli Lilly's #1 cash cow Zyprexa drug sale $38 billion dollars to date has a greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company also is a big profiteer of diabetes treatment.

All the best for Eli Lilly and resolution of Zyprexa claims
--Daniel Haszard Zyprexa victim activist